$CYTH
Cyclo Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000143774922026954 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $186.8K $452.2K $403.9K
YoY Change -68.07% 11.95% 81.57%
Cost Of Revenue $16.61K $35.21K $25.10K
YoY Change -77.44% 40.28% 151.0%
Gross Profit $170.2K $417.0K $378.8K
YoY Change -66.73% 10.07% 80.39%
Gross Profit Margin 91.11% 92.21% 93.79%
Selling, General & Admin $1.963M $1.804M $2.396M
YoY Change 4.09% -24.7% 327.84%
% of Gross Profit 1153.58% 432.7% 632.47%
Research & Development $3.185M $2.856M $1.838M
YoY Change 125.18% 55.42% 69.1%
% of Gross Profit 1871.41% 685.0% 485.12%
Depreciation & Amortization $4.870K $5.130K $4.210K
YoY Change 15.68% 21.85%
% of Gross Profit 2.86% 1.23% 1.11%
Operating Expenses $5.153M $2.856M $1.838M
YoY Change 55.93% 55.42% 69.1%
Operating Profit -$4.983M -$4.249M -$3.859M
YoY Change 78.39% 10.09% 168.73%
Interest Expense $2.480K $1.620K -$1.240K
YoY Change 166.67% -230.65%
% of Operating Profit
Other Income/Expense, Net $1.620K -$1.240K
YoY Change -230.65% -417.95%
Pretax Income -$4.980M -$4.247M -$3.860M
YoY Change 78.36% 10.02% 168.89%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.980M -$4.247M -$3.860M
YoY Change 78.36% 10.02% 168.89%
Net Earnings / Revenue -2666.18% -939.23% -955.7%
Basic Earnings Per Share -$0.50 -$0.60
Diluted Earnings Per Share -$0.59 -$502.7K -$598.7K
COMMON SHARES
Basic Shares Outstanding 8.482M 8.439M 6.438M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.543M $4.290M $8.441M
YoY Change -90.71% -49.18% 276.84%
Cash & Equivalents $1.543M $4.290M $8.441M
Short-Term Investments
Other Short-Term Assets $2.306M $3.466M $1.897M
YoY Change 12.08% 82.69% 59.42%
Inventory $254.5K $271.1K $253.8K
Prepaid Expenses
Receivables $54.99K $394.6K $354.9K
Other Receivables $0.00 $0.00 $45.07K
Total Short-Term Assets $4.159M $8.422M $10.99M
YoY Change -78.6% -23.38% 176.74%
LONG-TERM ASSETS
Property, Plant & Equipment $55.19K $60.06K $63.79K
YoY Change -7.38% -5.85% 11.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $56.66K $65.73K $104.4K
YoY Change -32.95% -37.02% -34.94%
TOTAL ASSETS
Total Short-Term Assets $4.159M $8.422M $10.99M
Total Long-Term Assets $56.66K $65.73K $104.4K
Total Assets $4.215M $8.488M $11.10M
YoY Change -78.41% -23.51% 168.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.481M $2.870M $3.294M
YoY Change -5.36% -12.87% -26.15%
Accrued Expenses $0.00 $4.980K $18.88K
YoY Change -100.0% -73.62% 88.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $106.8K
YoY Change -100.0% -100.0% 22.21%
Total Short-Term Liabilities $3.481M $2.875M $3.420M
YoY Change -9.14% -15.92% -25.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $44.91K
YoY Change -100.0% -100.0% -36.84%
Other Long-Term Liabilities $4.980K
YoY Change -83.4%
Total Long-Term Liabilities $0.00 $0.00 $49.89K
YoY Change -100.0% -100.0% -48.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.481M $2.875M $3.420M
Total Long-Term Liabilities $0.00 $0.00 $49.89K
Total Liabilities $3.481M $2.875M $3.469M
YoY Change -9.57% -17.13% -25.5%
SHAREHOLDERS EQUITY
Retained Earnings -$63.80M -$58.82M -$45.56M
YoY Change 31.96% 29.11% 45.17%
Common Stock $849.00 $846.00 $646.00
YoY Change 0.95% 30.96% -96.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $734.5K $5.612M $7.627M
YoY Change
Total Liabilities & Shareholders Equity $4.215M $8.488M $11.10M
YoY Change -78.41% -23.51% 168.52%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$4.980M -$4.247M -$3.860M
YoY Change 78.36% 10.02% 168.89%
Depreciation, Depletion And Amortization $4.870K $5.130K $4.210K
YoY Change 15.68% 21.85%
Cash From Operating Activities -$2.747M -$3.181M -$3.027M
YoY Change 5.17% 5.11% 88.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.49K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $28.77K $6.820K
YoY Change -100.0% 321.85% -31.8%
Cash From Investing Activities $0.00 $18.28K $6.820K
YoY Change -100.0% 168.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -1.780K
YoY Change -100.0% -100.0% -100.06%
NET CHANGE
Cash From Operating Activities -2.747M -3.181M -3.027M
Cash From Investing Activities 0.000 18.28K 6.820K
Cash From Financing Activities 0.000 0.000 -1.780K
Net Change In Cash -2.747M -3.163M -3.022M
YoY Change -133.61% 4.68% -347.69%
FREE CASH FLOW
Cash From Operating Activities -$2.747M -$3.181M -$3.027M
Capital Expenditures $0.00 -$10.49K $0.00
Free Cash Flow -$2.747M -$3.171M -$3.027M
YoY Change 5.17% 4.76% 88.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8455452
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8455452
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8403869
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8403869
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52900 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4247000 usd
us-gaap Net Income Loss
NetIncomeLoss
-10470000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58819000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12367000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4290000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2021Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6447803
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
8428074
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
6040524
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-25466
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-3029743
dei Entity Address Address Line1
EntityAddressAddressLine1
6714 NW 16th Street, Suite B
dei Entity Address City Or Town
EntityAddressCityOrTown
Gainesville
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32653
dei City Area Code
CityAreaCode
386
dei Local Phone Number
LocalPhoneNumber
418-8060
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
8481848
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4290198 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16612711 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
394570 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
493113 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
271137 usd
CY2021Q4 us-gaap Inventory Net
InventoryNet
227437 usd
CY2022Q3 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
0 usd
CY2021Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
45977 usd
CY2022Q3 us-gaap Prepaid Insurance
PrepaidInsurance
115889 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
42246 usd
CY2022Q3 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
3350002 usd
CY2021Q4 ctdh Prepaid Expenses Current Excluding Prepaid Insurance
PrepaidExpensesCurrentExcludingPrepaidInsurance
2014851 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
8421796 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
19436335 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60058 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
59583 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5669 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17636 usd
CY2022Q3 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
0 usd
CY2021Q4 us-gaap Long Term Accounts Notes And Loans Receivable Net Noncurrent
LongTermAccountsNotesAndLoansReceivableNetNoncurrent
7279 usd
CY2022Q3 us-gaap Assets
Assets
8487523 usd
CY2021Q4 us-gaap Assets
Assets
19520833 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4978 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19245 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
0 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
133712 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2870085 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3677979 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2875063 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3830936 usd
CY2022Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 usd
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
18034 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
846 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
841 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64430566 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
64019513 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58818952 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48348491 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5612460 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15671863 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8487523 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19520833 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
452167 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
403918 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1188957 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1000641 usd
CY2022Q3 us-gaap Salaries And Wages
SalariesAndWages
887506 usd
CY2021Q3 us-gaap Salaries And Wages
SalariesAndWages
1668010 usd
us-gaap Salaries And Wages
SalariesAndWages
3075170 usd
us-gaap Salaries And Wages
SalariesAndWages
2769526 usd
CY2022Q3 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
33032 usd
CY2021Q3 ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
22671 usd
ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
123163 usd
ctdh Cost Of Goods And Services Sold Excluding Direct And Indirect Overhead And Handling Costs
CostOfGoodsAndServicesSoldExcludingDirectAndIndirectOverheadAndHandlingCosts
87425 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2856160 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1837720 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5814595 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7739379 usd
CY2022Q3 ctdh Repairs And Maintenance
RepairsAndMaintenance
2177 usd
CY2021Q3 ctdh Repairs And Maintenance
RepairsAndMaintenance
2425 usd
ctdh Repairs And Maintenance
RepairsAndMaintenance
10175 usd
ctdh Repairs And Maintenance
RepairsAndMaintenance
5738 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
611685 usd
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
450490 usd
us-gaap Professional Fees
ProfessionalFees
1673582 usd
us-gaap Professional Fees
ProfessionalFees
1046979 usd
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
204654 usd
CY2021Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
244343 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
790441 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
799856 usd
CY2022Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
98126 usd
CY2021Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
30708 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
314382 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
30708 usd
CY2022Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
5129 usd
CY2021Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
4207 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
14611 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
12620 usd
CY2022Q3 ctdh Freight And Shipping
FreightAndShipping
2198 usd
CY2021Q3 ctdh Freight And Shipping
FreightAndShipping
2360 usd
ctdh Freight And Shipping
FreightAndShipping
11819 usd
ctdh Freight And Shipping
FreightAndShipping
5154 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
4700667 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
4262934 usd
us-gaap Costs And Expenses
CostsAndExpenses
11827938 usd
us-gaap Costs And Expenses
CostsAndExpenses
12497385 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4248500 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3859016 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-10638981 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11496744 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1620 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1240 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9996 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2475 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1620 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1240 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
168520 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2475 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4246880 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3860256 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10470461 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11494269 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4246880 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3860256 usd
us-gaap Net Income Loss
NetIncomeLoss
-10470461 usd
us-gaap Net Income Loss
NetIncomeLoss
-11494269 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8447630
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6447803
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8428074
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6040524
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15671863 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
106738 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2771591 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
13048014 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
15750 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
41256 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
87012 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-3451990 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
9740042 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
30752 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
88546 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4246880 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
5612460 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10452482 usd
CY2021Q1 ctdh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
7584092 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4036615 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
14321567 usd
CY2021Q2 ctdh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
402009 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-3597398 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-11126178 usd
CY2021Q3 ctdh Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
124998 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
231134 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3860256 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
7627054 usd
us-gaap Net Income Loss
NetIncomeLoss
-10470461 usd
us-gaap Net Income Loss
NetIncomeLoss
-11494269 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14611 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12620 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
158524 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-0 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-21755 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
282296 usd
us-gaap Share Based Compensation
ShareBasedCompensation
231134 usd
ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
15750 usd
ctdh Sharebased Compensation Employees
SharebasedCompensationEmployees
396306 usd
ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
113012 usd
ctdh Sharebased Compensation Nonemployees
SharebasedCompensationNonemployees
50300 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-120298 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
283847 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
43700 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15888 usd
ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
1335151 usd
ctdh Increase Decrease Prepaid Clinical Expenses
IncreaseDecreasePrepaidClinicalExpenses
1076712 usd
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
73643 usd
us-gaap Increase Decrease In Prepaid Insurance
IncreaseDecreaseInPrepaidInsurance
-33991 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-0 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
90 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-810194 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-247172 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-1897000 usd
us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-53256 usd
us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
-26988 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38170 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12367461 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12393627 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15086 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22500 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12322513 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4488 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7991101 usd
ctdh Proceeds From Issuance Repayments Of Longterm Debt
ProceedsFromIssuanceRepaymentsOfLongtermDebt
-8159 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-899358 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4404816 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16612711 usd
ctdh Proceeds From Issuance Repayments Of Longterm Debt
ProceedsFromIssuanceRepaymentsOfLongtermDebt
-6778 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6778 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7984323 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12846113 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4290198 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8441297 usd
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
21800 usd
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
52900 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(q) USE OF ESTIMATES––The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions, including regarding contingencies, that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company’s most significant estimates relate to inventory obsolescence, stock-based compensation and warrant liability valuation. Although management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, actual results could significantly differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q3 ctdh Working Capital Deficit
WorkingCapitalDeficit
5547000 usd
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
452167 usd
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
403918 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1188957 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1000641 usd
CY2016Q1 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
10000 usd
CY2016Q1 srt Mortgage Loans On Real Estate Face Amount Of Mortgages
MortgageLoansOnRealEstateFaceAmountOfMortgages
265000 usd
CY2016Q1 ctdh Mortgage Loans On Real Estate Monthly Payment
MortgageLoansOnRealEstateMonthlyPayment
3653 usd
CY2016Q1 srt Mortgage Loans On Real Estate Interest Rate
MortgageLoansOnRealEstateInterestRate
0.0425 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
226746
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-4246880 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3860256 usd
us-gaap Net Income Loss
NetIncomeLoss
-10470461 usd
us-gaap Net Income Loss
NetIncomeLoss
-11494269 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
8447630
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.60
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.90

Files In Submission

Name View Source Status
0001437749-22-026954-index-headers.html Edgar Link pending
0001437749-22-026954-index.html Edgar Link pending
0001437749-22-026954.txt Edgar Link pending
0001437749-22-026954-xbrl.zip Edgar Link pending
ctdh-20220930.xsd Edgar Link pending
ctdh20220930_10q.htm Edgar Link pending
ex_444041.htm Edgar Link pending
ex_444042.htm Edgar Link pending
ex_444043.htm Edgar Link pending
ex_444044.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ctdh20220930_10q_htm.xml Edgar Link completed
ctdh-20220930_cal.xml Edgar Link unprocessable
ctdh-20220930_def.xml Edgar Link unprocessable
ctdh-20220930_lab.xml Edgar Link unprocessable
ctdh-20220930_pre.xml Edgar Link unprocessable